These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 25112801)

  • 1. Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population.
    Priyadharsini R; Shewade DG; Subraja K; Ravindra BK; Umamaheswaran G; Dkhar SA; Satheesh S; Sridhar MG; Narayan SK; Adithan C
    Mol Biol Rep; 2014 Nov; 41(11):7265-71. PubMed ID: 25112801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.
    Arya V; Mahajan P; Saraf A; Mohanty A; Sawhney JP; Bhargava M
    Int J Lab Hematol; 2015 Dec; 37(6):809-18. PubMed ID: 26264906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
    Park KW; Kang J; Park JJ; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
    Heart; 2012 Sep; 98(18):1366-72. PubMed ID: 22735685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
    Isordia-Salas I; Olalde-Román MJ; Santiago-Germán D; de la Peña NC; Valencia-Sánchez JS
    Thromb Res; 2012 Sep; 130(3):e67-72. PubMed ID: 22819265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel.
    Mirzaev KB; Samsonova KI; Potapov PP; Andreev DA; Grishina EA; Ryzhikova KA; Sychev DA
    Mol Biol Rep; 2019 Aug; 46(4):4195-4199. PubMed ID: 31102151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
    Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
    Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation.
    Galić E; Vrbanić L; Kapitanović S; Catela Ivković T; Petro D; Vuković I; Bsharat RS; Milicević Z; Vcev A; Mirat J
    Coll Antropol; 2013 Jun; 37(2):491-8. PubMed ID: 23940995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene.
    Staritz P; Kurz K; Stoll M; Giannitsis E; Katus HA; Ivandic BT
    Int J Cardiol; 2009 Apr; 133(3):341-5. PubMed ID: 18485500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.
    Suh JW; Koo BK; Zhang SY; Park KW; Cho JY; Jang IJ; Lee DS; Sohn DW; Lee MM; Kim HS
    CMAJ; 2006 Jun; 174(12):1715-22. PubMed ID: 16754899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
    Smith SM; Judge HM; Peters G; Armstrong M; Fontana P; Gaussem P; Daly ME; Storey RF
    Platelets; 2006 Jun; 17(4):250-8. PubMed ID: 16769602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between CYP3A5 polymorphisms and the risk of adverse events in patients undergoing clopidogrel therapy: Meta-analysis.
    Wang YQ; Wang CH; Zhang JH
    Thromb Res; 2016 Nov; 147():1-6. PubMed ID: 27649539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship between human platelet antigen-1 gene polymorphism and clopidogrel resistance in patients with coronary artery disease].
    Tanboğa IH; Can MM; Ozkan A; Tokgöz HC; Akgün T; Koca F; Kurt M; Kaymaz C
    Turk Kardiyol Dern Ars; 2013 Jul; 41(5):379-85. PubMed ID: 23917001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance.
    Wang XD; Zhang DF; Liu XB; Lai Y; Qi WG; Luo Y; Hu B; Yao YA
    Eur J Intern Med; 2012 Jan; 23(1):48-53. PubMed ID: 22153531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
    Frere C; Cuisset T; Morange PE; Quilici J; Camoin-Jau L; Saut N; Faille D; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Am J Cardiol; 2008 Apr; 101(8):1088-93. PubMed ID: 18394438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease.
    Zhang LJ; Zhang YQ; Han X; Zhang ZT; Zhang ZQ
    Am J Ther; 2016; 23(6):e1663-e1670. PubMed ID: 25738571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance.
    Al-Husein BA; Al-Azzam SI; Alzoubi KH; Khabour OF; Nusair MB; Alzayadeen S
    J Cardiovasc Pharmacol; 2018 Dec; 72(6):296-302. PubMed ID: 30422888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.